CLYM20151 / S1925 / Barr
Research Question:
cancer study
Basic Study Information
Purpose:
This phase III trial compares early treatment with venetoclax and obinutuzumab versus
delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed
high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is
in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop
the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Starting treatment with the venetoclax and obinutuzumab early
(before patients have symptoms) may have better outcomes for patients with chronic
lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment
with the venetoclax and obinutuzumab after patients show symptoms.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Paul Barr
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search